March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

AM-Pharma raises $52M series C extension
AM-Pharma B.V. raised €47 million ($51.7 million) in an additional close of its series C round, bringing the total funds raised in the round to €163 million. The round was led by Cowen Healthcare Investments and the European Investment Bank. The company expects to start this half a Phase III trial of reCAP, a recombinant human alkaline phosphatase, to treat sepsis-associated-acute kidney injury (see “AM-Pharma Raises €116M Series C”).

Zucara raises $21M A round
Zucara Therapeutics Inc. raised $21 million in a series A round led by the Perceptive Xontogeny Venture Fund. The company plans to start a Phase I trial mid-year of SSTR2 antagonist ZT-01 to prevent hypoglycemia in patients with Type I diabetes; the funds will also support Phase II testing (see "Suppressing Somatostatin")...